Camurus ABCAMRF -3.57%79 Net Margin % is 26.98% as of Mar. 2026. GuruFocus rates CAMRF with a GF Score™ of 79/100 and a GF Value™ of $83.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 947 Biotechnology companies, Camurus AB ranks better than 91.02% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Camurus AB's Net Income for the
three
months ended in Mar. 2026 was $15.4 Mil. Camurus AB's Revenue for the
three
months ended in Mar. 2026 was $57.2 Mil. Therefore, Camurus AB's net margin for the quarter that ended in Mar. 2026 was 26.98%.
The historical rank and industry rank for Camurus AB's Net Margin % or its related term are showing as below:
CAMRF'
s Net Margin % Range Over the Past 10 Years
Min: -475.81 Med: -32.42 Max: 32.47
Current: 30.45
CAMRF's Net Margin % is ranked better than 91.02% of 947
companies
in the Biotechnology industry
Industry Median: -89.56
vs CAMRF: 30.45
Camurus AB (OTCPK:CAMRF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Camurus AB Net Margin % Related Terms
Camurus AB Net Margin % Historical Data
* Premium members only.
The historical data trend for Camurus AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Camurus AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Camurus AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a Net Margin % of 26.98% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Camurus AB and its competitors. According to the industry distribution chart, Camurus AB ranks #85 out of 947 companies in the Biotechnology industry, placing it in the top 9%.
Is Camurus AB's Net Margin % too high?
Camurus AB's current Net Margin % is 26.98%. Based on the distribution chart, Camurus AB ranks #85 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #85 out of 947 companies for Net Margin %. This places Camurus AB in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Camurus AB and its competitors. Camurus AB's current Net Margin % is 26.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.14, compared to a current price of $54.00 — trading 35% below its estimated fair value. The current Net Margin % is 26.98%. Camurus AB's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Net Margin % is 26.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $54.00 is trading 35% below its estimated GF Value™ of $83.14.
GuruFocus considers Camurus AB to be Significantly Undervalued.
Key valuation signals for CAMRF:
Net Margin %: 26.98%
GF Value™: $83.14 vs. price of $54.00 (35% below fair value)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score
Get the complete analysis for CAMRF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
